Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 179 clinical trials
Arsenic Trioxide in Refractory Solid Tumors With Rescuable p53 Mutation

This study is an open, prospective, single arm, multi center exploratory basket clinical study. 20 refractory solid tumors patients with rescuable p53 mutation will be enrolled, and the efficacy and safety of arsenic trioxide in those patients will be evaluated.

  • 0 views
  • 24 May, 2021
  • 1 location
Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation. (COLUMBUS-AD)

The purpose of the Columbus-AD study is to evaluate the efficacy and safety of 12 months of encorafenib in combination with binimetinib in adjuvant setting of BRAF V600E/K mutant stage IIB/C

  • 0 views
  • 29 Jul, 2022
  • 13 locations
Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations

This BVD-523-ABC study builds on the safety and clinical activity experience of previous studies that have evaluated ulixertinib as a novel targeted cancer treatment in cohorts of patients with specific genetic alterations and tumor histologies that result in aberrant MAPK pathway signaling. Early clinical data have demonstrated anti-tumor activity with …

  • 0 views
  • 11 Aug, 2022
  • 23 locations
Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma

This is a multicenter Phase 1b, open-label study to evaluate the pharmacokinetic, safety and efficacy of binimetinib and encorafenib co-administered to adolescent patients with BRAF V600-mutant

metastasis
braf v600e mutation
metastatic cutaneous melanoma
malignant melanoma of skin
cancer
  • 24 views
  • 06 Jun, 2022
  • 6 locations
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of KIN-2787 in adults with BRAF/NRAS-mutated advanced or metastatic solid

BRAF
cancer
braf inhibitor
NRAS
  • 0 views
  • 09 Aug, 2022
  • 17 locations
A Study of VS-6766 and VS-6766 + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer (RAMP202)

This study will assess the safety and efficacy of VS-6766 monotherapy or VS-6766 in combination with defactinib in subjects with recurrent Non-small cell lung cancer.

measurable disease
BRAF
KRAS
recurrent non-small cell lung cancer
lung carcinoma
  • 1 views
  • 24 Jul, 2022
  • 40 locations
Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases (CAIRO5)

prospectively confirmed by an expert panel according to predefined criteria, will be tested for RAS and BRAF tumor mutation status and selected by location of primary tumor. Patients with RAS or BRAF mutant and

primary tumor
metastasis
folfiri regimen
neutrophil count
liver surgery
  • 249 views
  • 07 Apr, 2022
  • 50 locations
Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib (EBIN)

+ ipilimumab alone in patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.

measurable disease
metastatic melanoma
BRAF
ipilimumab
ct scan
  • 11 views
  • 16 Feb, 2022
  • 39 locations
A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma

> is advanced or metastatic (spread to other parts of the body); has a certain type of abnormal gene called "BRAF"; and has not received prior treatment.

metastatic melanoma
malignant melanoma of skin
pembrolizumab
systemic therapy
measurable disease
  • 0 views
  • 08 Aug, 2022
  • 39 locations
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

: has spread to other parts of the body (metastatic); has a certain type of abnormal gene called "BRAF"; and has not received prior treatment. Participants

metastasis
cetuximab
primary cancer
BRAF
immunostimulants
  • 0 views
  • 20 Jun, 2022
  • 129 locations